<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">tumors</journal-id><journal-title-group><journal-title xml:lang="ru">Malignant tumours</journal-title><trans-title-group xml:lang="en"><trans-title>Malignant tumours</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2224-5057</issn><issn pub-type="epub">2587-6813</issn><publisher><publisher-name>Rosoncoweb</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18027/2224-5057-2018-8-4-45-49</article-id><article-id custom-type="elpub" pub-id-type="custom">tumors-585</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Ассоциация генов XRCC1, HMMR с развитием рака молочной железы в кыргызской популяции</article-title><trans-title-group xml:lang="en"><trans-title>Association of XRCC1, HMMR genes with breast cancer in the Kyrgyz ethnic group</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семетей кызы</surname><given-names>А.</given-names></name><name name-style="western" xml:lang="en"><surname>Semetei kyzy</surname><given-names>A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант кафедры онкологии и лучевой терапии</p></bio><bio xml:lang="en"><p>MD, Researcher of the Oncology and Radiotherapy Department</p></bio><email xlink:type="simple">aigul9206@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Макимбетов</surname><given-names>Э. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Makimbetov</surname><given-names>E. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д. м. н., проф. кафедры онкологии и лучевой терапии</p></bio><bio xml:lang="en"><p>MD, DSc Med, Professor, Oncology and Radiotherapy Department</p></bio><email xlink:type="simple">makimbetov@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Исакова</surname><given-names>Ж. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Isakova</surname><given-names>J. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д. м. н., с. н. с.</p></bio><bio xml:lang="en"><p>MD, DSc Med, Senior Researcher</p></bio><email xlink:type="simple">jainagul@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кудайбергенова</surname><given-names>И. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Kudaibergenova</surname><given-names>I. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д. м. н., проф. кафедры онкологии</p></bio><bio xml:lang="en"><p>MD, DSc Med, Professor, Oncology Department</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Камарли</surname><given-names>З. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Kamarli</surname><given-names>Z. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д. м. н., проф., зав. кафедрой онкологии и лучевой терапии</p></bio><bio xml:lang="en"><p>MD, DSc Med, Professor, Head of the Oncology and Radiotherapy Department</p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Кыргызско-Российский Славянский Университет, Бишкек</institution><country>Кыргызстан</country></aff><aff xml:lang="en"><institution>Kyrgyz Russian Slavic University, Bishkek</institution><country>Kyrgyzstan</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>НИИ молекулярной биологии и медицины, Бишкек</institution><country>Кыргызстан</country></aff><aff xml:lang="en"><institution>Research Institute of Molecular Biology and Medicine, Bishkek</institution><country>Kyrgyzstan</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Кыргызская Государственная Медицинская Академия, Бишкек</institution><country>Кыргызстан</country></aff><aff xml:lang="en"><institution>Kyrgyz State Medical Academy, Bishkek</institution><country>Kyrgyzstan</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Кыргызско-Российский Славянский Университет, Бишкек</institution><country>Кыргызстан</country></aff><aff xml:lang="en"><institution>Kyrgyz Russian Slavic University , Bishkek</institution><country>Kyrgyzstan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>22</day><month>01</month><year>2019</year></pub-date><volume>8</volume><issue>4</issue><fpage>45</fpage><lpage>49</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Семетей кызы А., Макимбетов Э.К., Исакова Ж.Т., Кудайбергенова И.О., Камарли З.П., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Семетей кызы А., Макимбетов Э.К., Исакова Ж.Т., Кудайбергенова И.О., Камарли З.П.</copyright-holder><copyright-holder xml:lang="en">Semetei kyzy A., Makimbetov E.K., Isakova J.T., Kudaibergenova I.O., Kamarli Z.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.malignanttumors.org/jour/article/view/585">https://www.malignanttumors.org/jour/article/view/585</self-uri><abstract><p>Влияние генов XRCC1, HMMR на развитие рака молочной железы в кыргызской популяции ранее не было изучено. В исследовании приняли участие 99 женщин кыргызской этнической группы с морфологически верифицированным диагнозом рак молочной железы (РМЖ), получавшие стационарное лечение в Национальном центре онкологии и Диагностическом центре «КафМедЦентр» (г. Бишкек, Кыргызская Республика). Средний возраст пациентов составил 53 года (24–74, SE mean = 0,967, STD=9,81). В контрольную группу вошли 102 условно здоровые женщины кыргызской этнической группы, находящиеся в той же возрастной категории, что и исследуемые. Генотипирование осуществлялось методом ПЦР-ПДРФ. При сравнении результатов генотипирования, гистологической структуры опухоли и фактора «менопауза» использовался точный критерий Фишера. Расчет отношения шансов проводился путем построения таблицы кросс-табуляции. Показано, что для генотипа Arg / Arg полиморфного локуса Arg194Trp гена XRCC1 имеется статистически значимая ассоциация с фактором «менопауза». У женщин в менопаузе генотип Аrg / Arg полиморфного локуса Arg194Trp гена XRCC1 встречается с частотой 52 %, тогда как у женщин до наступления менопаузы этот же генотип встречается с частотой 78,8 % (р=0,009). Также было установлено, что генотип СС полиморфного локуса V353A гена HMMR является «протективным» фактором и ассоциирован с низким риском развития РМЖ в  кыргызской популяции (ОШ=0,481, 95 % ДИ=0,272–0,850). Кроме того, не было выявлено статистически значимой ассоциации между результатами генотипирования и гистологической структурой опухоли, а также возрастом верификации диагноза.</p></abstract><trans-abstract xml:lang="en"><p>An association of genes XRCC1 and HMMR with breast cancer (BC) has never been tested in the Kyrgyz ethnic group. This was a case-control study of 201 women of the Kyrgyz ethnic group with a morphologically verified breast cancer (N=99) and 102 controls age-matched with BC cases. The mean age of the patients was 53 years (24–74, SE mean = 0.967, STD=9.81). The extraction of DNA was carried out from venous blood. The genotyping was conducted by using the method of polymerase chain reaction and restriction fragment length polymorphism. When comparing the results of genotyping, the histological structure of the tumor and the «menopause» factor, Fisher»s exact test was used. Calculation of the odds ratio was carried out by cross tabulation method. A statistically significant link between the XRCC1 Arg194Trp polymorphism and the menopausal status was observed (p=0,018). The Arg / Arg genotype of XRCC1 Arg194Trp polymorphism occurred in 52 % of cases in women at menopausal age, whereas in women before the onset of menopause, the genotype Arg / Arg occurred in 78.8 % of BC cases (p=0.009). The CT genotype of HMMR V353A polymorphism was identified as “protective” factor – OR=0.481, 95 % CI [0.27‑0.85]. There was no statistically significant association between the results of genotyping and histological structure of the tumor, as well as the age of verification of the diagnosis of BC.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>полиморфизм</kwd><kwd>XRCC1</kwd><kwd>HMMR</kwd><kwd>кыргызская популяция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>polymorphism</kwd><kwd>XRCC1</kwd><kwd>HMMR</kwd><kwd>Kyrgyz ethnic group</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Sieber O. M., Heinimann K., Tomlinson I. P. Genomic instability – the engine of tumorigenesis? Nat. Rev. Cancer. 2003. Vol. 3. P. 701–708.</mixed-citation><mixed-citation xml:lang="en">Sieber O. M., Heinimann K., Tomlinson I. P. Genomic instability – the engine of tumorigenesis? Nat. Rev. Cancer. 2003. Vol. 3. P. 701–708.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Sultana R., Abdel-Fatah T., Abbotts R., Hawkes C., Albarakati N. Targeting XRCC1 Deficiency in Breast Cancer for Personalized Therapy. Cancer Res. 2013. Vol. 73 (5). P. 1621–1634. DOI: 10.1158 / 0008‑5472.CAN-12‑2929 2013.</mixed-citation><mixed-citation xml:lang="en">Sultana R., Abdel-Fatah T., Abbotts R., Hawkes C., Albarakati N. Targeting XRCC1 Deficiency in Breast Cancer for Personalized Therapy. Cancer Res. 2013. Vol. 73 (5). P. 1621–1634. DOI: 10.1158 / 0008‑5472.CAN-12‑2929 2013.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ladiges W. C. Mouse models of XRCC1 DNA repair polymorphisms and cancer. Oncogene. 2006. Vol. 25. P. 1612–1619.</mixed-citation><mixed-citation xml:lang="en">Ladiges W. C. Mouse models of XRCC1 DNA repair polymorphisms and cancer. Oncogene. 2006. Vol. 25. P. 1612–1619.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Horton J. K., Watson M., Stefanick D. F., Shaughnessy D. T., Taylor J. A., Wilson S. H. XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res. 2008. Vol. 18. P. 48–63.</mixed-citation><mixed-citation xml:lang="en">Horton J. K., Watson M., Stefanick D. F., Shaughnessy D. T., Taylor J. A., Wilson S. H. XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res. 2008. Vol. 18. P. 48–63.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang R., Niu Y., Zhou Y. Increase the cisplatin cytotoxicity and cisplatin-induced DNA damage in HepG2 cells by XRCC1 abrogation related mechanisms. Toxicol. Lett. 2010. Vol. 192. P. 108–114.</mixed-citation><mixed-citation xml:lang="en">Zhang R., Niu Y., Zhou Y. Increase the cisplatin cytotoxicity and cisplatin-induced DNA damage in HepG2 cells by XRCC1 abrogation related mechanisms. Toxicol. Lett. 2010. Vol. 192. P. 108–114.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Tischkowitz M., Xia B., Sabbaghian N. et al. Analysis of PALB2 / FANCN-associated breast cancer families. Proc. Natl. Acad. Sci. USA. 2007. Vol. 104. P. 6788–6793.</mixed-citation><mixed-citation xml:lang="en">Tischkowitz M., Xia B., Sabbaghian N. et al. Analysis of PALB2 / FANCN-associated breast cancer families. Proc. Natl. Acad. Sci. USA. 2007. Vol. 104. P. 6788–6793.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Rahman N., Seal S., Thompson D., Kelly P., Renwick A., Elliott A., Reid S., Spanova K., Barfoot R., Chagtai T. et al. PALB2, which encodes a BRCA2‑interacting protein, is a breast cancer susceptibility gene. Cancer. 2007. Vol. 39. P. 165–167.</mixed-citation><mixed-citation xml:lang="en">Rahman N., Seal S., Thompson D., Kelly P., Renwick A., Elliott A., Reid S., Spanova K., Barfoot R., Chagtai T. et al. PALB2, which encodes a BRCA2‑interacting protein, is a breast cancer susceptibility gene. Cancer. 2007. Vol. 39. P. 165–167.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Akent’eva N. P., Shushanov S. S., Kotelnikov A. I. Effects of RHAAM / HMMR – selective peptides on survival of breast cancer cells. Bulletin of Experimental Biology and Medicine. 2015. Vol. 159. No. 5. P. 658–661.</mixed-citation><mixed-citation xml:lang="en">Akent’eva N. P., Shushanov S. S., Kotelnikov A. I. Effects of RHAAM / HMMR – selective peptides on survival of breast cancer cells. Bulletin of Experimental Biology and Medicine. 2015. Vol. 159. No. 5. P. 658–661.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Lejeune F. J., Ruegg C., Lienard D. Clinical applications of TNF-alpha in cancer. Curr. Opin. Immunol. 1998. Vol. 10. P. 573–580.</mixed-citation><mixed-citation xml:lang="en">Lejeune F. J., Ruegg C., Lienard D. Clinical applications of TNF-alpha in cancer. Curr. Opin. Immunol. 1998. Vol. 10. P. 573–580.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001. Vol. 357. P. 539–545</mixed-citation><mixed-citation xml:lang="en">Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001. Vol. 357. P. 539–545</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Res. 2002. Vol. 13. P. 135–141.</mixed-citation><mixed-citation xml:lang="en">Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Res. 2002. Vol. 13. P. 135–141.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Leek R. D., Landers R., Fox S. B., Ng F., Harris A. L. et al. (1998) Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Brit. J. Cancer. 1998. Vol. 77. P. 2246–2251.</mixed-citation><mixed-citation xml:lang="en">Leek R. D., Landers R., Fox S. B., Ng F., Harris A. L. et al. (1998) Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Brit. J. Cancer. 1998. Vol. 77. P. 2246–2251.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
